China's state food and drug administrator approved Jiangsu Lianhuan Pharmaceutical's (SHA:600513) Famotidine injection, according to a Saturday filing with the Shanghai bourse.
Shares closed 5% higher on Monday.
The injection inhibits the secretion of gastric acid and is a histamine H2 receptor blocker, the drug company said.
H2 receptor blockers are used in the treatment of gastroesophageal reflux disease and heartburn, the US National Institutes of Health said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments